Alopecia Areata Market Poised for Significant Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 hours ago
0mins
Should l Buy ABBV?
Source: Newsfilter
- Market Growth: The alopecia areata treatment market is expected to see significant growth by 2036, with 1.7 million diagnosed cases projected in the 7MM by 2025, indicating strong market demand.
- Emerging Therapies: The launch of new therapies such as RINVOQ and Bempikibart is set to intensify competition, with promising clinical trial results suggesting they could transform the current treatment landscape.
- Impact of JAK Inhibitors: The approval of JAK inhibitors like OLUMIANT and LITFULO provides new treatment options, with clinical trials demonstrating significant efficacy in promoting hair regrowth, attracting increased payer interest.
- Expanding Patient Pool: With an estimated 620,000 diagnosed cases in the U.S. by 2024, the expanding patient population is expected to drive market demand, prompting pharmaceutical companies to invest more in the development of new therapies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 228.720
Low
223.00
Averages
252.00
High
289.00
Current: 228.720
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alopecia Areata Market Poised for Significant Growth
- Market Growth: The alopecia areata treatment market is expected to see significant growth by 2036, with 1.7 million diagnosed cases projected in the 7MM by 2025, indicating strong market demand.
- Emerging Therapies: The launch of new therapies such as RINVOQ and Bempikibart is set to intensify competition, with promising clinical trial results suggesting they could transform the current treatment landscape.
- Impact of JAK Inhibitors: The approval of JAK inhibitors like OLUMIANT and LITFULO provides new treatment options, with clinical trials demonstrating significant efficacy in promoting hair regrowth, attracting increased payer interest.
- Expanding Patient Pool: With an estimated 620,000 diagnosed cases in the U.S. by 2024, the expanding patient population is expected to drive market demand, prompting pharmaceutical companies to invest more in the development of new therapies.
See More
Record Surge in Drug Licensing Deals from China
- Surge in Deal Count: According to PharmCube, the Greater China region signed 186 cross-border licensing deals worth $137.7B in 2025, marking a nearly tenfold increase from 65 deals valued at $13.9B in 2021, highlighting the growing appeal of the Chinese market for global pharmaceutical companies.
- Industry Trend Analysis: As several blockbuster drugs face patent expirations, leading drugmakers increasingly rely on licensing deals to replenish their pipelines, with projections indicating a potential $200B revenue loss for the global pharmaceutical industry from 2026 to 2030, making China a crucial licensing market.
- Expansion of Deal Size: The average deal size in 2026 stands at $1.3B, reflecting a ~76% increase from 2025 and approximately six times the average size in 2021, driven by AstraZeneca's obesity drug deal worth up to $18.5B with CSPC Pharmaceutical and AbbVie's cancer drug deal worth up to $5.6B with RemeGen.
- Ongoing Attraction: So far in 2026, 38 deals have been reached with a total value approaching $49B, demonstrating the sustained interest of international pharmaceutical companies in the Chinese market, particularly under the pressure of patent expirations.
See More
Investment Outlook for the U.S. Healthcare Sector in 2024
- Healthcare Sector Size: U.S. healthcare spending is projected to exceed $5.3 trillion in 2024, representing nearly one-fifth of the U.S. economy, highlighting the sector's immense investment potential and attracting long-term investor interest.
- AbbVie's Growth Potential: AbbVie (ABBV), with its diverse treatment portfolio and over 50 years of dividend growth history, is expected to achieve over 17% annual earnings growth, making it a top choice for investors.
- Eli Lilly's Market Leadership: Eli Lilly (LLY) has established itself as a leader in the obesity drug market, with tirzepatide driving success; the market is expected to reach $144 billion by 2030, with anticipated annual earnings growth of 25%.
- Bristol Myers Squibb's Challenges and Opportunities: Despite facing patent expirations, Bristol Myers Squibb (BMY) has a strong oncology pipeline and a projected 15% annual earnings growth, indicating significant upside potential for investors.
See More
AbbVie Declares Quarterly Dividend of $1.73 per Share
- Dividend Declaration: AbbVie has declared a quarterly dividend of $1.73 per share, consistent with previous distributions, indicating the company's stable cash flow and shareholder return strategy, which is expected to bolster investor confidence.
- Yield Analysis: The forward yield of 3.04% offers relative attractiveness in the current market environment, potentially drawing in income-seeking investors and further solidifying AbbVie's position in the healthcare sector.
- Shareholder Record Date: The dividend will be payable on May 15, with a record date of April 15 and an ex-dividend date also on April 15, ensuring shareholders receive timely returns and enhancing their willingness to hold shares.
- Market Performance: This week, 22 out of 23 healthcare firms reported earnings per share growth, reflecting strong overall industry performance, which may positively impact AbbVie's stock price.
See More
AbbVie Declares Quarterly Cash Dividend of $1.73
- Quarterly Cash Dividend: AbbVie's board has declared a cash dividend of $1.73 per share, payable on May 15, 2026, to shareholders of record as of April 15, 2026, demonstrating the company's ongoing profitability and commitment to shareholder returns.
- Significant Dividend Growth: Since its inception in 2013, AbbVie has increased its dividend by over 330%, reflecting the company's robust financial health and enhancing investor confidence in its long-term investment value.
- Dividend Aristocrat Membership: AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have increased their dividends annually for at least 25 consecutive years, further validating its exceptional performance and market position in shareholder returns.
- Innovative Mission: AbbVie is dedicated to discovering and delivering innovative medicines that address serious health issues today and tackle future medical challenges, spanning key therapeutic areas such as immunology, neuroscience, and oncology, highlighting the company's strategic significance in the healthcare industry.
See More
AbbVie Declares Quarterly Cash Dividend of $1.73
- Quarterly Cash Dividend: AbbVie's board has declared a cash dividend of $1.73 per share, payable on May 15, 2026, to shareholders of record as of April 15, 2026, demonstrating the company's ongoing financial health and commitment to shareholder returns.
- Significant Dividend Growth: Since its inception in 2013, AbbVie has increased its dividend by over 330%, reflecting not only improved profitability but also bolstering investor confidence in its long-term investment value.
- Dividend Aristocrat Membership: As a member of the S&P Dividend Aristocrats Index, AbbVie has consistently raised its dividend for 25 consecutive years, further solidifying its reputation among stable income investors.
- Innovative Mission: AbbVie is dedicated to discovering and delivering innovative medicines that address serious health issues today and future medical challenges, covering key therapeutic areas such as immunology, neuroscience, and oncology, highlighting its strategic importance in the healthcare sector.
See More
Alopecia Areata Market Poised for Significant Growth
- Market Growth: The alopecia areata treatment market is expected to see significant growth by 2036, with 1.7 million diagnosed cases projected in the 7MM by 2025, indicating strong market demand.
- Emerging Therapies: The launch of new therapies such as RINVOQ and Bempikibart is set to intensify competition, with promising clinical trial results suggesting they could transform the current treatment landscape.
- Impact of JAK Inhibitors: The approval of JAK inhibitors like OLUMIANT and LITFULO provides new treatment options, with clinical trials demonstrating significant efficacy in promoting hair regrowth, attracting increased payer interest.
- Expanding Patient Pool: With an estimated 620,000 diagnosed cases in the U.S. by 2024, the expanding patient population is expected to drive market demand, prompting pharmaceutical companies to invest more in the development of new therapies.
See More
Record Surge in Drug Licensing Deals from China
- Surge in Deal Count: According to PharmCube, the Greater China region signed 186 cross-border licensing deals worth $137.7B in 2025, marking a nearly tenfold increase from 65 deals valued at $13.9B in 2021, highlighting the growing appeal of the Chinese market for global pharmaceutical companies.
- Industry Trend Analysis: As several blockbuster drugs face patent expirations, leading drugmakers increasingly rely on licensing deals to replenish their pipelines, with projections indicating a potential $200B revenue loss for the global pharmaceutical industry from 2026 to 2030, making China a crucial licensing market.
- Expansion of Deal Size: The average deal size in 2026 stands at $1.3B, reflecting a ~76% increase from 2025 and approximately six times the average size in 2021, driven by AstraZeneca's obesity drug deal worth up to $18.5B with CSPC Pharmaceutical and AbbVie's cancer drug deal worth up to $5.6B with RemeGen.
- Ongoing Attraction: So far in 2026, 38 deals have been reached with a total value approaching $49B, demonstrating the sustained interest of international pharmaceutical companies in the Chinese market, particularly under the pressure of patent expirations.
See More
Investment Outlook for the U.S. Healthcare Sector in 2024
- Healthcare Sector Size: U.S. healthcare spending is projected to exceed $5.3 trillion in 2024, representing nearly one-fifth of the U.S. economy, highlighting the sector's immense investment potential and attracting long-term investor interest.
- AbbVie's Growth Potential: AbbVie (ABBV), with its diverse treatment portfolio and over 50 years of dividend growth history, is expected to achieve over 17% annual earnings growth, making it a top choice for investors.
- Eli Lilly's Market Leadership: Eli Lilly (LLY) has established itself as a leader in the obesity drug market, with tirzepatide driving success; the market is expected to reach $144 billion by 2030, with anticipated annual earnings growth of 25%.
- Bristol Myers Squibb's Challenges and Opportunities: Despite facing patent expirations, Bristol Myers Squibb (BMY) has a strong oncology pipeline and a projected 15% annual earnings growth, indicating significant upside potential for investors.
See More
AbbVie Declares Quarterly Dividend of $1.73 per Share
- Dividend Declaration: AbbVie has declared a quarterly dividend of $1.73 per share, consistent with previous distributions, indicating the company's stable cash flow and shareholder return strategy, which is expected to bolster investor confidence.
- Yield Analysis: The forward yield of 3.04% offers relative attractiveness in the current market environment, potentially drawing in income-seeking investors and further solidifying AbbVie's position in the healthcare sector.
- Shareholder Record Date: The dividend will be payable on May 15, with a record date of April 15 and an ex-dividend date also on April 15, ensuring shareholders receive timely returns and enhancing their willingness to hold shares.
- Market Performance: This week, 22 out of 23 healthcare firms reported earnings per share growth, reflecting strong overall industry performance, which may positively impact AbbVie's stock price.
See More
AbbVie Declares Quarterly Cash Dividend of $1.73
- Quarterly Cash Dividend: AbbVie's board has declared a cash dividend of $1.73 per share, payable on May 15, 2026, to shareholders of record as of April 15, 2026, demonstrating the company's ongoing profitability and commitment to shareholder returns.
- Significant Dividend Growth: Since its inception in 2013, AbbVie has increased its dividend by over 330%, reflecting the company's robust financial health and enhancing investor confidence in its long-term investment value.
- Dividend Aristocrat Membership: AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have increased their dividends annually for at least 25 consecutive years, further validating its exceptional performance and market position in shareholder returns.
- Innovative Mission: AbbVie is dedicated to discovering and delivering innovative medicines that address serious health issues today and tackle future medical challenges, spanning key therapeutic areas such as immunology, neuroscience, and oncology, highlighting the company's strategic significance in the healthcare industry.
See More
AbbVie Declares Quarterly Cash Dividend of $1.73
- Quarterly Cash Dividend: AbbVie's board has declared a cash dividend of $1.73 per share, payable on May 15, 2026, to shareholders of record as of April 15, 2026, demonstrating the company's ongoing financial health and commitment to shareholder returns.
- Significant Dividend Growth: Since its inception in 2013, AbbVie has increased its dividend by over 330%, reflecting not only improved profitability but also bolstering investor confidence in its long-term investment value.
- Dividend Aristocrat Membership: As a member of the S&P Dividend Aristocrats Index, AbbVie has consistently raised its dividend for 25 consecutive years, further solidifying its reputation among stable income investors.
- Innovative Mission: AbbVie is dedicated to discovering and delivering innovative medicines that address serious health issues today and future medical challenges, covering key therapeutic areas such as immunology, neuroscience, and oncology, highlighting its strategic importance in the healthcare sector.
See More
